CytoMed Therapeutics (GDTC)
Develops donor-derived and iPSC-based cell therapies for cancer.
Something off on this page? Send us feedback.
Develops off-the-shelf, donor-derived gamma-delta T-cell and iPSC-derived gamma-delta NKT therapies for cancer. Its early clinical lead and research-stage platforms have no product-sales revenue; potential future routes include approved-product commercialization, licensing, and partnering.
Develops allogeneic cancer cell therapies around donor-derived gamma-delta T cells and iPSC-derived gamma-delta natural-killer-T cells. CTM-N2D, the lead non-genetically modified candidate, uses healthy-donor cells expanded outside the body as an off-the-shelf investigational therapy in an early clinical study. Other platforms, including engineered-cell research, remain research or preclinical programs.
Runs research, process development, and manufacturing-related work across Singapore and Malaysia as a single research-and-development operation. With no approved product or product-sales revenue, potential commercial routes include approval-led commercialization, licensing, collaboration, and partnering. Trial progress depends on clinical proof, regulatory review, manufacturing consistency, licensed technology rights, liquidity, and continued Nasdaq-listing compliance.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $1.6M · Total debt $377.2K · Total assets $6.2M · Shareholders' equity $5.1M
- Revenue
- $131.3K
- Operating income
- −$1.8M
- Net income
- −$1.4M
Reported in SGD, converted at the latest exchange rate
No dividends on record.
| Insiders | 29.98% | 3.55M ADS | |
|---|---|---|---|
| 6 holders · as of Jul 24, 2026 | |||
| Strategic holders | 69.12% | 8.18M ADS | |
| 4 holders · as of Mar 24, 2025 | |||
| Other | 0.90% | 107.0K ADS | |
| remainder | |||
11.83M ADS as of Sep 2, 2026 · holders as of their latest filing
The share count is from the company's Apr 2024 annual report; nothing newer is on file here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Finance LimitedStrategic | 39.33% | 4.65M | filed Apr 21, 2023 |
Chee Kong ChooInsiderdirector, 10 percent owner | 24.51% | 2.90M ordinary | filed Jul 24, 2026 |
LimitedStrategic | 11.30% | 1.34M | filed Feb 14, 2024 |
mDR LTDStrategic | 11.05% | 1.31M | filed Mar 24, 2025 |
28 Consultants LtdStrategic | 7.44% | 880,313 | filed Mar 4, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 14, 2026 | Chee Kong Choo | director, 10 percent owner: | +200,000 | $1.50 |
| Jul 20, 2026 | Chee Kong Choo | director, 10 percent owner: | +200,000 | $1.50 |
| May 13, 2026 | Chee Kong Choo | director, 10 percent owner: | +112,000 | $1.15 |
- Adicet Bio
Allogeneic gamma-delta CAR-T platform in oncology.
- IN8bio
Gamma-delta T-cell programs in blood cancers and glioblastoma.
- Century Therapeutics
Renewable iPSC-derived allogeneic immune-cell platform.
- Fate
Off-the-shelf iPSC-derived CAR T and CAR NK platform.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CytoMed Therapeutics | $0.8846 | −2.79% | $10.8M | — | — | — | +30.5% |
| Adicet Bio | $9.01 | −1.48% | $85.5M | — | — | — | — |
| IN8bio | $1.13 | −0.88% | $10.9M | — | — | — | — |
| Century Therapeutics | $1.86 | −1.82% | $163.6M | — | — | — | — |
| Fate | $2.55 | −1.16% | $300.7M | — | — | 46.3 | +9.2% |
| Median | — | — | 46.3 | +9.2% |